The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma

Area of Science:

• Oncology
• Immunology
• Metabolic pathways

Background:

• Metastatic pancreatic adenocarcinoma has a dismal 5-year survival rate of 3%.
• Current systemic chemotherapies like gemcitabine, FOLFIRINOX, and gemcitabine with nab-paclitaxel offer limited long-term benefit, with most patients eventually progressing.
• There is a critical need for novel therapeutic targets to improve treatment efficacy.

Purpose of the Study:

• To review emerging systemic therapies for pancreatic cancer.
• To explore strategies for enhancing anti-tumor immunity.
• To investigate the targeting of tumor metabolic pathways for therapeutic benefit.

Main Methods:

• Review of current clinical investigations.
• Analysis of the tumor microenvironment (TME) and its role in immune evasion.
• Examination of key metabolic vulnerabilities in pancreatic cancer cells.

Main Results:

• Deeper understanding of the TME reveals opportunities to boost anti-tumor immunity.
• Identification of critical metabolic pathways essential for tumor survival presents novel therapeutic targets.
• Several promising approaches are currently under clinical investigation.

Conclusions:

• Novel therapeutic strategies focusing on tumor immunity and metabolism show promise for pancreatic cancer.
• These next-generation therapies may offer improved outcomes beyond current chemotherapy limitations.
• Further clinical investigation is warranted to establish the efficacy of these emerging treatments.